NVCR at a glance
NovoCure Ltd (NVCR, SEC CIK 1645113) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on July 23, 2026, an 8-K current report on October 1, 2026 and Form 4 insider filings as recently as July 1, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), NovoCure Ltd (NVCR) reported revenue of $655.4 million (up 8.3% from FY2024) and a net loss of $136.2 million. Diluted EPS was -$1.22.
- As of June 30, 2026, 29 institutional investment managers tracked by SignalX reported holding NovoCure Ltd (NVCR) shares worth $961.5 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Leonard Frank X on June 4, 2026 of 34,273 shares at $17.93 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $655.4M
- +8.3% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 29 funds
- $961.5M · +1 vs prior quarter
- Latest 8-K
- Oct 1, 2026
- Item 7.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Risk Factors
- FDA PMA approval dependency for Optune Gio sales; majority revenue from newly diagnosed and recurrent GBM indications
- Geopolitical risk from Greater China market reliance on Zai partnership for development and commercialization
- Production dependency on third-party manufacturers for sufficient quality and quantity of Products
- Competition risk from alternative therapies impacting market acceptance despite FDA and CE approvals
- Historical substantial operating losses with intermittent profits; ongoing high commercialization and R&D expenses
Management Discussion & Analysis
- Revenue and profitability details not provided in the provided MD&A excerpt
- Cash flow, capital allocation, and buybacks or dividends details absent
- Forward-looking guidance or emerging risks not mentioned in the excerpt
Business Overview
- Core business model: Commercialization of TTFields therapy devices (Optune Gio, Lua, Pax) delivering electric fields to kill cancer cells for solid tumor cancers
- New emphasis on brain metastases from NSCLC with September 2025 Phase 3 METIS trial showing 28% lower risk of intracranial progression; Optune Mya PMA submitted, FDA review ongoing
- Strategic expansion to pancreatic cancer with 2026 FDA approval of Optune Pax based on PANOVA-3 trial; survival improved to 16.2 vs 14.2 months (p=0.039)
- Sales force grew to 217 globally as of December 2025; estimated 8,200 GBM, 30,000 NSCLC, 15,000 pancreatic cancer patients in U.S. eligible and seeking treatment in 2026
- Unusual milestone: simultaneous regulatory progress with multiple devices; PMA filing acceptance for brain metastases (Optune Mya) and first U.S. approval for pancreatic cancer device Optune Pax
AI summary of the NVCR 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- No profitability, margin, segment, cash flow, capital deployment, or outlook figures disclosed
Risk Factors
- No risk factors provided; excerpt contains Items 2–6 and signatures only
- No new or changed risks identifiable from the supplied filing text
AI summary of the NVCR 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Japan MHLW approval expands Optune Pax® into unresectable locally advanced pancreatic cancer
- Approval covers adult patients receiving gemcitabine and nab-paclitaxel
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Director Timothy Scannell retired effective September 2, 2026 after five years of board service
- Board seat formally vacated under the Company’s Articles of Association
Item 8.01: Other Events
- Unauthorized systems access discovered in mid-August 2026; investigation and containment remain ongoing
- Data exposed from over 1,400 U.S. patient records, plus fewer than 50 patients’ identifying information
Item 1.05: Material Cybersecurity Incidents
- Standard forward-looking statement disclaimer covering clinical development, regulatory approvals, manufacturing, market prospects, and payer coverage
- Investor focus: execution and regulatory risks could materially affect Novocure’s future performance and financial results
AI summaries of NVCR 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for NVCR
Don't miss the next NVCR filing
- Alerts as it files. A push when NVCR files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut NVCR, by share count.
- Ask anything. An AI agent that reads every NVCR filing and answers with sources.
NVCR alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Puri Michal Nath | A | Jun 30, 2026 | 1,905 | $11.15 |
| Danziger Asaf | A | Jun 30, 2026 | 268 | $11.15 |
| Leonard Frank X | A | Jun 30, 2026 | 1,905 | $11.15 |
| Ben Arye Barak | A | Jun 30, 2026 | 1,299 | $11.15 |
| Leonard Frank X | Sell | Jun 4, 2026 | 34,273 | $17.93 |
| LEUNG GABRIEL | A | Jun 3, 2026 | 16,999 | - |
| LEUNG GABRIEL | A | Jun 3, 2026 | 11,610 | - |
| HILLEMAN JERYL L | A | Jun 3, 2026 | 11,610 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $509.3M | $605.2M | $655.4M |
| Gross Profit | - | $468.0M | $488.5M |
| Operating Income | - | -$170.5M | -$153.8M |
| Net Income | - | -$168.6M | -$136.2M |
| Gross Margin | - | 77.3% | 74.5% |
| Op. Margin | - | -28.2% | -23.5% |
| Net Margin | - | -27.9% | -20.8% |
| Balance Sheet | |||
| Total Assets | - | $1.2B | $804.3M |
| Equity | $362.5M | $360.2M | $340.5M |
| ROE | - | -46.8% | -40.0% |
| Per Share | |||
| EPS | - | $-1.56 | $-1.22 |
| Cash Flow | |||
| Operating CF | - | -$26.4M | -$49.0M |
| CapEx | - | $42.9M | $26.6M |
Source: XBRL data in NovoCure Ltd (NVCR)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate NVCR share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 29 | $961.5M |
| Q1 2026 | 28 | $638.2M |
| Q4 2025 | 26 | $749.9M |
| Q3 2025 | 27 | $681.3M |
| Q2 2025 | 29 | $931.9M |
| Q1 2025 | 26 | $653.9M |
| Q4 2024 | 26 | $1.06B |
| Q3 2024 | 20 | $116.1M |
- AQR Capital Management+827.2K (+301%)
- JPMorgan Chase & Co+740.9K (+80%)
- Bank of America Corp+592.7K (+349%)
- Renaissance Technologies LLC+400.4K (+26%)
- D.E. Shaw & Co+375.4K (+58%)
- Wells Fargo & Co−423.1K (-14%)
- Two Sigma Investments−24.1K (-53%)
- Morgan Stanley−19.1K (-0%)
- U.S. Bancorp−1.1K (-85%)
- PNC Financial Services−689 (-87%)
- Allstate+18.8K
- First Bancorp, Inc /ME/+2.5K
- Fifth Third Bancorp−2.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 211 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
NVCR filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Oct 1, 2026 | - | Analysis | - |
| 8-K | Sep 9, 2026 | - | Analysis | - |
| 8-K | Sep 1, 2026 | - | Analysis | - |
| 8-K | Jul 23, 2026 | - | Analysis | - |
| 10-Q | Jul 23, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 8-K | Jun 30, 2026 | - | Analysis | - |
| 8-K | Jun 18, 2026 | - | Analysis | - |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 8-K | Jun 5, 2026 | - | Analysis | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
NVCR SEC filings: frequently asked questions
Which institutions hold NVCR stock?
As of June 30, 2026, the largest NovoCure Ltd (NVCR) holders among the 13F filers tracked by SignalX were FMR LLC (Fidelity) ($263.2 million), BlackRock ($203.2 million), Vanguard Portfolio Management LLC ($95.0 million), Vanguard Capital Management LLC ($74.3 million), Morgan Stanley ($68.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was NVCR's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), NovoCure Ltd (NVCR) reported revenue of $655.4 million (up 8.3% from FY2024) and a net loss of $136.2 million. Diluted EPS was -$1.22. The figures come from the XBRL data in the 10-K.
What are the main risks in NVCR's latest 10-K?
In the 10-K filed February 26, 2026, NovoCure Ltd (NVCR) flagged: FDA PMA approval dependency for Optune Gio sales; majority revenue from newly diagnosed and recurrent GBM indications. Geopolitical risk from Greater China market reliance on Zai partnership for development and commercialization. (AI summary of the Risk Factors section.)
What did NVCR report in its latest 8-K?
NovoCure Ltd (NVCR) filed an 8-K on October 1, 2026 reporting Item 7.01 (Regulation FD Disclosure). Japan MHLW approval expands Optune Pax® into unresectable locally advanced pancreatic cancer.
What are the latest NVCR SEC filings?
NovoCure Ltd (NVCR) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on July 23, 2026, an 8-K current report on October 1, 2026 and a Form 4 insider filing on July 1, 2026.
What is NVCR's SEC CIK number?
NovoCure Ltd (NVCR)'s SEC Central Index Key (CIK) is 1645113. EDGAR lists every NVCR filing under that number.
Ask anything about NVCR
The research agent reads NVCR's filings, financials, insider trades and 13F holders, then answers with sources.